Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPCOM: Influence of Proton Pump Inhibitor Co-medication on Mycophenolate Mofetil Absorption
2024-517043-32-00Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil and pantoprazole in immunocompromise, sponsored by Leiden University Medical Center. Primary endpoints: Maximum plasma concentration (Cmax) of mycophenolic acid (MPA) and Area under the concentration-time curve AUC(0–12) of mycophenolic acid (MPA). Started Feb 2025; status: completed.
02
Drugs
mycophenolate mofetilpantoprazole
03
Conditions
immunocompromise
Beyond the preview
Go deeper on 2024-517043-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517043-32-00.